In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including:

• Prognostic variables when deciding between regimens
• Role of MRD in CLL
• Results from the phase II CAPTIVATE trial
• Choosing among the available covalent BTK inhibitors
• Preferred partner anti-CD20 antibody in CLL/SLL
• Role of the noncovalent BTK inhibitor, pirtobrutinib, in CLL/SLL
• Use of CAR T-cell therapy in CLL/SLL

Presenters:

Farrukh Awan, MD
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Jeremy S. Abramson, MD, MMSc
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Shuo Ma, MD, PhD
Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University 
Feinberg School of Medicine
Chicago, Illinois

Content based on an online CME program supported by educational grants from BeiGene; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly, and an independent medical education grant from AbbVie.

Link to full program:
https://bit.ly/3LzA2As

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.